DoH, USCF and IGI Explore Establishing the World's first-of-their kind Centres for Genome Surgery
ABU DHABI, UAE, July 4, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics Institute (IGI) to explore the establishment of the world's first-of-their-kind centres for genome surgery in Abu Dhabi and California. Formalised during a strategic visit to the United States, the collaboration seeks to accelerate the Emirate's efforts to lead in genomic medicine and advance personalised genetic therapy, transforming the future of healthcare delivery for the global community.
Genome surgery is an experimental medical technique aimed at modifying or replacing faulty genes within cells to treat or prevent diseases. This is achieved through personalised genetic therapies or by using advanced technologies such as CRISPR, which can be tailored specifically to each patient based on their unique genetic mutations.
These new centres would enable the diagnosis and correction of severe genetic conditions as early as possible to improve outcomes. Leveraging CRISPR-based technologies, the Centres would offer customised, genome-guided interventions that have the potential to transform patient outcomes and redefine the future of healthcare.
H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, commented: "This collaboration reflects Abu Dhabi's determination to pioneer real-world applications of advanced science. Partnering with UCSF and IGI, one of the world's most respected institutions in gene therapy, would accelerate our ability to integrate genome-guided care into our healthcare system, creating an unprecedented opportunity to correct genetic conditions early in life, prevent chronic disease progression and reduce long-term healthcare costs".
By combining Abu Dhabi's state-of-the-art healthcare infrastructure and genomic data capabilities with UCSF's global leadership in pediatric and fetal therapy and IGI's cutting-edge research in gene editing, the partnership would drive the development and delivery of innovative, real-world solutions for patients with early-onset, severe, rare and inherited diseases.
Dr. Tippi MacKenzie, Director of the UCSF Broad Stem Cell Center, at University of California, San Francisco (UCSF), said: "This is an extraordinary time to be in medicine, when we have the opportunity to develop life-saving therapies for patients with severe genetic conditions. We are excited by the possibility of developing mirrored programs that coalesce multidisciplinary expertise and link the myriad steps between diagnosing a genetic disease and developing and implementing a safe genome surgery strategy."
The collaboration would also prioritise building national expertise by training a new generation of Emirati professionals in genomic surgery and clinical innovation. By intervening early in life-threatening or debilitating conditions, the initiative would build capacity to support families, reduce dependence on lifelong treatments, and ease pressure on the healthcare system, cementing Abu Dhabi's position as a global destination for advanced genomic care and life sciences innovation.
Dr. Fyodor Urnov, Professor of Molecular Therapeutics at the University of California, Berkeley, and Director of the IGI-Danaher Beacon for CRISPR Cures, said: "This year marks a landmark achievement for science and medicine of a CRISPR gene-editing therapeutic designed and administered on-demand to an infant with a severe inborn error of metabolism in record time. The mission of the Innovative Genomics Institute as defined by its founder, Jennifer Doudna, winner of the 2020 Nobel Prize for CRISPR gene editing, is to make it the standard of medical care, no matter where such a child is born. The IGI's deep partnership with Danaher that made an enabling contribution to the on-demand gene edit earlier this year provides an outstanding technological and manufacturing foundation for scaling such therapeutic approaches. We are honored to partner with world-leading clinical expertise at UCSF to explore how we may ultimately expand CRISPR on demand to children living with severe genetic diseases in the UAE."
This exploratory partnership aligns with Abu Dhabi's broader vision to embed genomics into public health and drive a shift toward personalised and preventive care. Central to this effort is the Emirati Genome Programme, which has sequenced over 800,000 genomes to date, to create one of the most diverse national databases globally. The programme has enabled key initiatives such as the national pharmacogenomics reporting system (PGx), with over 160,000 reports now available to help tailor treatment plans based on individual genetic profiles. Additional milestones include the integration of genetic testing into the Premarital Screening Programme, the launch of the Newborn Genetic Screening Programme, and the development of the Emirati Reference Genome platform. These efforts are supported by the upskilling of over 100 Emirati physicians in genomic medicine and counselling through advanced training initiatives, strengthening local expertise in this critical field.
View original content:https://www.prnewswire.com/apac/news-releases/doh-uscf-and-igi-explore-establishing-the-worlds-first-of-their-kind-centres-for-genome-surgery-302498289.html
SOURCE The Department of Health - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ("CER-T") therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM. LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial. Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, "Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response." This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster. For more information about LabPMM's flow cytometry and molecular testing services, please visit or contact us at inquiry@ and follow us on LinkedIn. About Invivoscribe Inc. Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. 1 2 View source version on Contacts inquiry@ Connectez-vous pour accéder à votre portefeuille
Yahoo
2 hours ago
- Yahoo
Asm. Dr. Jasmeet Bains expected to announce 2026 congressional bid against David Valadao
BAKERSFIELD, Calif. (KGET) — The political fallout from Congress passing President Donald Trump's 'Big Beautiful Bill' is hitting close to home. Kern County Republican Congressman David Valadao is especially in the hot seat, with his 2026 reelection bid on the line and Assemblywoman Dr. Jasmeet Bains eyes his seat. She's been vocal in hinting at a congressional run, but now she's really vocal. 'We're a little less than a year out, but the election has already started,' said Christian Romo, chair of the Kern County Democratic Party. Kern County's US House Reps. Valadao, Fong vote 'yes' for Trump's mega budget bill We're one step closer to knowing the players in the 2026 midterm election — specifically, the hopefuls for the House of Representatives. 'Dr. Jasmeet Bains. Surprises exactly no one who's following politics,' said Central Valley political strategist Tracy Leach. For months now, there's been speculation the Democratic representative of California's 35th Assembly District and family doctor is eyeing Capitol Hill. 'She's perfectly positioned to run on those issues and be the instant expert on healthcare,' Leach said. Romo agreed. 'Timing certainly is in Bains' favor,' he said 'Medicaid and Medicare are top issues.' Perfect timing, a result of the Republican budget bill that was signed into law by President Donald Trump Friday. Trump keeps saying the GOP mega bill will eliminate taxes on Social Security. It does not It's a budget expected to cut hundreds of billions in federal funding for health care. CD-22 Republican incumbent David Valadao is defending his yes vote. Immediately after the House floor, he said in a statement in part: 'Ultimately, I voted for this bill because it does preserve the Medicaid program for its intended recipients — children, pregnant women, the disabled, and elderly. The bill also includes dozens of other policy provisions that directly benefit CA-22.' When asked if Valadao was caught between his constituents and party, Leach remarked: 'Yes, I think he got significant pressure from his party, but they're going to have to do a really good job to marketing the upside because the Democrats are coming after him for that vote.' Democrats like Bains. She posted on X: 'I took an oath to protect my patients and my community overwhelmingly elected me to office to fight for them because they know I am not afraid to go to any length to protect them. It might be time to call in the Doctor!' And on Facebook she also wrote, 'It's time for change and looks like it's time to call the Doctor in.' 'Agonizing': How Alaska's pivotal Republican senator decided to vote for Donald Trump's bill 'If she entered right now would be the frontrunner,' Romo acknowledged. 'It's a matter of when.' 'Get your popcorn out. It's going to be, once again, a barn burner,' Leach noted of 2026 and this race in particular. Bains did not respond to request for comment but has said in the past, 'I really hope I don't have to step into the race.' And in May, Bains partnered on an advertisement with a political action committee called Healthcare Saves Lives, funded by SEIU CA and local health care and homecare unions. In that ad, she introduces herself as a family doctor and states, 'Tell Congressman Valadao to stop these cuts on Medi-Cal.' Another big question — who would replace Bains in the Assembly? Romo hinted Bakersfield City Councilmember Andrae Gonzales is a very likely candidate. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CNN
8 hours ago
- CNN
CDC ends emergency response to H5N1 bird flu
Respiratory viruses Federal agencies FacebookTweetLink The US Centers for Disease Control and Prevention says it has ended its emergency response to H5N1 bird flu, citing a drop in cases. 'As reports of animal infections with avian influenza A(H5N1) virus ('H5N1 bird flu') have declined and no human cases have been reported since February 2025, on July 2, 2025, CDC's H5N1 emergency bird flu response was deactivated to transition back to regular program activity,' a spokesperson for the US Department of Health and Human Services said in a statement Monday. The spokesperson said that surveillance, readiness and response for influenza – including H5N1 bird flu – will continue under the CDC's influenza division and other appropriate agency programs. Dr. Nirav Shah, who resigned this year from his position as CDC principal deputy director, says he would have also chosen to end the emergency response. 'This was not something that was imposed from the top down. It was initiated by the career scientists at CDC,' said Shah, now a visiting professor at Colby College in Maine. 'The rationale is, in short, there haven't been any human cases. And so there is not the need to sprint all-out every single day when there haven't been human cases in a while. If there were to be more human cases, it is very easy to ratchet back up the level of the intensity of the response. It can literally be done in an afternoon.' The end of the bird flu emergency was first reported by Bloomberg News. H5N1 was first identified in the late 1990s and has caused sporadic outbreaks around the world. Since 2022, the virus has affected nearly 175 million birds in the US, including wild birds, commercial flocks and backyard flocks. It has also spread to dozens of species of mammals in more than 100 countries around the world. In early 2024, the virus infected dairy cattle in the United States and became a threat to the dairy industry. Over the past 14 months, it spread to more than 1,000 herds across 17 states. A total of 70 human cases have been reported in the United States, with one death. The CDC H5N1 emergency was declared April 4, 2024, and allowed for additional support to the public health response, such as staffing. Reports of cases have slowed, but experts note that there's a seasonality to bird fu, with cases peaking in the fall or early winter. Changes at federal health agencies may mean some milder cases are going undetected, they say, but it's unlikely that serious cases are being missed. 'The current public health risk from H5N1 bird flu is low, however, CDC will continue to monitor the situation and scale up activities as needed,' the HHS spokesperson said.
